Full index of posts »
StockTalks
-
(CPST) stoploss at $1.10. Feb 28, 2012
-
(ARNA) I like the upside potential here. I will have a research article out this weekend. $5 to $8 potential upside. Jan 27, 2012
-
(CPST) I like the company. CPST has very good potential for a major short squeeze. limited downside risk and good upside reward. Breakout. Jan 24, 2012
Latest Comments
-
Jeffadler on Response To Mr. Feuerstein And The Street Com Regarding Keryx And AEterna The argument seems a bit moot now, doesn't it J...
-
bbrewski11 on Response To Mr. Feuerstein And The Street Com Regarding Keryx And AEterna I second the scum!!!!!
-
Tuppy on Response To Mr. Feuerstein And The Street Com Regarding Keryx And AEterna Your facts have not been correct as well. You s...
-
brophyct on Response To Mr. Feuerstein And The Street Com Regarding Keryx And AEterna Seems no one heard Jeremy Richards responce. Wo...
-
EthicsFirst on Response To Mr. Feuerstein And The Street Com Regarding Keryx And AEterna AG comment: OK this makes sense, the trial is t...
Most Commented
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.


















View Jeremy Richards' Instablogs on:
Response To Mr. Feuerstein And The Street Com Regarding Keryx And AEterna
I sincerely hope that Mr. Feuerstein can focus on true market issues and focus on facts rather than propagating false and misleading information.
Before investors take Mr. Feuerstein seriously I would highly recommend taking a look at the following site (exposeadam.com)The website is devoted to providing a forum to rebut and correct the numerous one sided articles written by Adam Feuerstein on behalf of the Street.com. Adam Feuerstein has been writing for the Street.com since 2001 and is marketed as their Senior Columnist although he has never attended journalism school nor does he have any formal education in Journalism. In fact, he has NO formal science background either (he was a political science major at Emory University) and thus his credibility and objectivity as a biotech journalist must be questioned. He has been sued by biotech companies for his one sided attacks. Additionally, his inaccurate reporting has even led to patient safety issues as outlined in this article about Oculus Innovative Sciences. There have been numerous articles written about his one sided tactics and his questionable timing and release of misleading headlines that can be found here. Under the guise of being a biotech journalist, Adam frequently writes misleading headlines and articles that are widely disseminated via the Street.com's media network.
Disclosure: I am long KERX, AEZS.